Post by Tony Crispino on Sept 21, 2016 21:47:34 GMT -8
The ECOG3805 also called the CHAARTED clinical trial testing early use of docetaxel chemotherapy in men with at least 4 metastatic lesions in the bone or visceral disease spread to organs was largely beneficial. That trial also was inconclusive in men with lesser mets. Expect that to change soon. And not for the better. It is expected to be announced soon that in fact, the CHAARTED trial will not be able to show any benefit in the men in the lesser mets setting. Thus it would then be that early use of docetaxel is clearly for the men with more advanced disease ONLY.
This means that other trials in that type of setting may be very important. The S1216 SWOG trial among them. For now, the use of chemo should come after the standard of care which is leuprolide acetate + bicalutamide. (or another LHRH agonist). And perhaps after second line therapies such as Zytiga and Xtandi fail.
This means that other trials in that type of setting may be very important. The S1216 SWOG trial among them. For now, the use of chemo should come after the standard of care which is leuprolide acetate + bicalutamide. (or another LHRH agonist). And perhaps after second line therapies such as Zytiga and Xtandi fail.